MARKET

PMN

PMN

Promis Neuroscie
NASDAQ
10.57
+0.08
+0.76%
After Hours: 10.54 -0.03 -0.28% 17:42 05/13 EDT
OPEN
10.36
PREV CLOSE
10.49
HIGH
10.80
LOW
10.36
VOLUME
8.77K
TURNOVER
--
52 WEEK HIGH
39.75
52 WEEK LOW
6.27
MARKET CAP
94.79M
P/E (TTM)
-0.4675
1D
5D
1M
3M
1Y
5Y
1D
ProMIS Neurosciences GAAP EPS of -$1.26
Seeking Alpha · 1d ago
ProMIS Neurosciences reports Q1 EPS ($1.26) vs. ($5.27) last year
TipRanks · 1d ago
Earnings Scheduled For May 12, 2026
Benzinga · 1d ago
ProMIS Neurosciences Q1 EPS $(1.26) Beats $(1.48) Estimate
Benzinga · 1d ago
ProMIS Neurosciences Q1 FY26 net loss widens to $8.24 million
PUBT · 1d ago
PROMIS NEUROSCIENCES ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE HIGHLIGHTS
Reuters · 1d ago
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
Barchart · 1d ago
Weekly Report: what happened at PMN last week (0504-0508)?
Weekly Report · 2d ago
More
About PMN
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

Webull offers Promis Neurosciences Inc stock information, including NASDAQ: PMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PMN stock methods without spending real money on the virtual paper trading platform.